|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
Genentech
1 DNA Way
South San Francisco
California
94080-4990
U.S.A.
Phone:
650-225-1000
Fax:
650-225-6000
|
Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.
On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.
Please view our company video on YouTube:
http://www.youtube.com/genentech#p/u/1/GJH4X5gxxf0
Connect with us via Social Media:
Facebook: www.facebook.com/GenentechJobs
Twitter: www.twitter.com/GenentechJobs
LinkedIn: www.linkedin.com/company/genentech
Email:
Ownership:
Subsidiary
Web Site:
Genentech
Employees:
10,000+
Symbol: RHHBY
|
|
|
Company News |
PDL BioPharma, Inc. (PDLI) Files for Arbitration Against Genentech (RHHBY) Based on Underpayment of Royalties
6/11/2013 7:08:53 AM
More...
|
Genentech (RHHBY)'s Avastin Fails Studies in New Brain Tumor Patients
6/3/2013 7:18:39 AM
More...
|
Genentech (RHHBY) Release: Despite Lucentis's Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
5/30/2013 9:22:52 AM
More...
|
The Logic of Biologics - Is Regeneron Pharmaceuticals, Inc. (REGN) the Next Genentech (RHHBY)?
5/22/2013 9:00:02 AM
More...
|
Genentech (RHHBY) and Biogen Idec, Inc. (Massachusetts) (BIIB) Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
5/17/2013 9:13:20 AM
More...
|
Genentech (RHHBY) Cancer Antibody, Son of Rituxan, Nails Pivotal Study
5/16/2013 7:35:57 AM
More...
|
Genentech (RHHBY) to Present Important New Data Reflecting Broad Cancer Pipeline at American Society of Clinical Oncology
5/15/2013 8:13:10 AM
More...
|
Genentech (RHHBY) Wins New FDA OK for Lung Cancer Drug, Diagnostic Test
5/15/2013 6:54:53 AM
More...
|
Another Biosimilar Legislative Defeat for Amgen (AMGN) & Genentech (RHHBY)
5/7/2013 7:47:32 AM
More...
|
NGM Biopharmaceuticals, Inc., Led by Genentech (RHHBY) Vets Levinson and Goeddel, Raises $13.5 Million
5/6/2013 9:33:29 AM
More...
|
|
|
|
 |
|
|
|
|
|
|
|
|
|